November 28, 2023, OrigiMed, a leading enterprise in China's precision diagnosis and treatment industry, announced the official commencement of its in vitro diagnostic reagent production base and high-end biopharmaceutical benchmark industry project in Quzhou. Upon completion, it will become the main in vitro diagnostic reagent production base for OrigiMed in China and create a high-end biopharmaceutical industry benchmark base in Quzhou. Zhou Xiaohong, a third-level investigator of the Quzhou Intelligent Manufacturing City Management Committee; Cheng Keyun, a member of the Party Committee and deputy director of the Quzhou Municipal Health Commission; Cheng Shengli, director of the Development Department of the Quzhou People's Hospital; Dr. Liu Xinwei, Chief Financial Officer of OrigiMed; Dr. Lu Leilei, Chief Operating Officer of OrigiMed; Wei Zhenge, a member of the Party Committee and deputy general manager of CSCEC-TAISEI, and the project management team attended the groundbreaking ceremony together, witnessing this exciting moment.

It is reported that the project is planned to be divided into two phases. During the first phase, it plans to build a 6,000 square meter of integrated IVD research and development and production center, which includes separate production areas, comprehensive R&D experimental areas, high-standard quality inspection areas, comprehensive office areas, and other ancillary production facilities, forming the production capacity for scaled companion diagnostic reagent kits and independent medical software. During the second phase, it plans to introduce domestic high-specification biopharmaceutical production lines and ancillary production facilities, high-end medical devices, etc., to create a high-end biopharmaceutical benchmark industry base, and by integrating and sharing multi-omics data such as clinical, pathological, follow-up, and molecular, to transform into pharmaceutical achievements, promoting the development of precision diagnosis and treatment and innovative drug industries. It is expected that upon full completion, it will create a high-end biopharmaceutical benchmark project that integrates a pharmaceutical R&D center, operation center, pharmaceutical CRO R&D center, and companion diagnostic reagent kit production base, promoting the integrated development of innovative pharmaceutical industry clusters.

Zhou Xiaohong, a third-level investigator of the Quzhou Intelligent Manufacturing City Management Committee, stated that as the main platform for Quzhou's industry, the Intelligent Manufacturing City focuses on the "5+X" leading industrial chains and strives to promote the development strategy of "industrial strength and industrial prosperity". OrigiMed, as a locally cultivated enterprise in precision oncology medicine, possesses international experience and a laboratory quality management system that meets international standards. After the delivery and operation of OrigiMed’s in vitro diagnostic reagent production and high-end biopharmaceutical benchmark industry project, it will provide strong support for the high-quality development of the life science and health industry in the Intelligent Manufacturing City, help build a cluster of life science and health industries in Quzhou, and promote the high-quality development of the regional medical technology industry.

Dr. Lu Leilei, Chief Operating Officer of OrigiMed, stated that as a leading enterprise in precision diagnosis and treatment of cancer in China, OrigiMed adheres to the development concept of "based on advanced sequencing technology and driven by real-world data," and is committed to promoting innovation in clinical cancer treatment in China. After years of development and effort, OrigiMed has achieved fruitful results in multiple areas including data, technology, pharmaceutical service capabilities, and cooperation with insurance companies. Among them, the NTRK 1/2/3 gene mutation detection kit co-developed with Bayer has passed the "Special Review for Innovative Medical Devices" approval by the Center for Medical Device Technology Evaluation of the National Medical Products Administration, and is about to be approved for market launch. In the future, OrigiMed will rely on the high-quality business environment of Quzhou Intelligent Manufacturing City to create a "Medical Silicon Valley based on real-world data and a benchmark production base for medical devices", promoting the integrated development of innovative pharmaceutical industry clusters.